The Mumbai Biocluster, comprising prestigious institutions like ICT Mumbai, IIT Bombay, TIFR, ACTREC, and Khalsa College, has been awarded Rs 60 crore by the Department of Science and Technology’s (DST) SATHI initiative to expedite the development of medicines.
The primary objective of the biocluster is to transform drug development processes within the country. It will act as an accelerator for startups, academia, MSMEs, and industries, offering cutting-edge infrastructure and expertise to facilitate the rapid development of biopharmaceutical products. Focusing on monoclonal antibodies, vaccines, mRNA technology, and cell & gene therapy, the facility will tackle critical challenges encountered during technology scale-up and validation in the drug development phase.
A key component of the biocluster’s mission is the establishment of a Good Manufacturing Practice (GMP) facility, which will enable affordable drug development, as stated by ICT Mumbai.
The Mumbai Biocluster aims to bridge the gap between research and commercialization, positioning India at the forefront of biopharmaceutical innovation. This endeavor is expected to drive economic growth and enhance healthcare outcomes, according to the statement.
